Clinical trial
A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease
NCT07305818 is registered in ClinicalTrials.gov with Merida Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease
- Lead sponsor
- Merida Biosciences
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 19, 2025
- Completion date
- July 24, 2028
- Enrollment
- 100 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.